- Previous Close
9.69 - Open
9.60 - Bid 9.10 x --
- Ask 9.52 x --
- Day's Range
9.21 - 9.75 - 52 Week Range
7.95 - 10.45 - Volume
10 - Avg. Volume
2,998 - Market Cap (intraday)
2.119B - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
-- - EPS (TTM)
-0.06 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield 0.18 (2.03%)
- Ex-Dividend Date May 12, 2023
- 1y Target Est
--
Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
www.almirall.com1,876
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 0O9B.IL
View MorePerformance Overview: 0O9B.IL
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0O9B.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0O9B.IL
View MoreValuation Measures
Market Cap
1.98B
Enterprise Value
2.01B
Trailing P/E
186.15
Forward P/E
15.50
PEG Ratio (5yr expected)
0.89
Price/Sales (ttm)
2.00
Price/Book (mrq)
1.33
Enterprise Value/Revenue
2.04
Enterprise Value/EBITDA
11.59
Financial Highlights
Profitability and Income Statement
Profit Margin
-1.23%
Return on Assets (ttm)
1.64%
Return on Equity (ttm)
-0.77%
Revenue (ttm)
898.36M
Net Income Avi to Common (ttm)
-11.04M
Diluted EPS (ttm)
-0.06
Balance Sheet and Cash Flow
Total Cash (mrq)
447.3M
Total Debt/Equity (mrq)
26.56%
Levered Free Cash Flow (ttm)
50.48M